AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca study tracks how two versions of its asthma drug move through children’s bodies. The official Phase I trial, “Phase I Study to Compare the Pharmacokinetics of Budesonide and Formoterol Delivered With Symbicort Aerosphere® and Symbicort® pMDI in Children 4 to Less Than 12 Years of Age With Asthma,” aims to compare drug exposure and safety, a key step for long term pediatric use and device strategy.
The treatments are two fixed dose inhalers that combine budesonide, a steroid that reduces airway swelling, and formoterol, a long acting drug that helps keep airways open. One uses the newer Symbicort Aerosphere device, the other the traditional Symbicort pMDI inhaler, and the goal is to see if they deliver similar levels of drug in young patients.
The trial is an interventional Phase I study with children who have asthma randomly assigned to different dosing sequences. Each child receives a single dose of each inhaler in a crossover design with no blinding, letting researchers compare how the same patient responds to both devices and focus on treatment effects, not disease outcomes.
The study is listed as recruiting, with initial submission on 20 Feb 2026, and the most recent update on 11 Mar 2026, showing active operational progress. Key timing milestones such as first dosing, primary completion, and full completion will matter for when AstraZeneca can submit pediatric data, though detailed completion dates are not yet posted and may shift as enrollment unfolds.
For investors, this update signals AstraZeneca’s push to strengthen the Symbicort franchise in younger patients and support the Aerosphere platform, which could help defend share against rivals in pediatric asthma. While Phase I data alone rarely move AZN stock sharply, steady pipeline execution in core respiratory assets supports sentiment, especially as peers like GSK and Novartis also expand inhaler portfolios.
The study remains ongoing and recently updated, with further details available on the ClinicalTrials portal.
To learn more about GB:AZN’s potential, visit the AstraZeneca plc drug pipeline page.